Vertex Is Down 13% Over 500 Days. What History Says Now.

Vertex Has Been Falling for 500 Days. Here is What History Says.

As of June 18, 2026, Vertex Pharmaceuticals Incorporated (VRTX) has entered a -12.6% price drawdown lasting 516 days, driving the stock from its green zone into the yellow zone. This price decline contrasts with the stock's internal valuation metrics: as of the valuation snapshot on 2026-06-18, the price-to-sales ratio of 9.6 sits in the 22nd percentile of its own historical record since 2006-06-19, while its EV-to-EBITDA ratio of 21.2 rests in the 33rd percentile since 2012-02-22. This divergence shows that while the stock price has fallen, the underlying valuation multiples are trading lower relative to the asset's own history rather than remaining elevated.

Vertex's Transition to a Moderately Elevated Drawdown Severity Score™

Our data shows that as of June 18, 2026, the Drawdown Severity Score™ for Vertex Pharmaceuticals Incorporated (VRTX) has reached 2.0. This score indicates a Moderately Elevated risk profile, shifting the stock from its previous green zone into the yellow zone. The Drawdown Severity Score™ measures the depth and duration of a pullback relative to an asset's historical behavior to help investors identify when a sell-off departs from normal trading patterns.

A -12.6% drawdown is not unprecedented for the stock, but the duration of this decline is what stands out. The stock has spent 516 days in this drawdown cycle since peaking at its all-time high of $516.74. This duration is significantly longer than the average drawdown duration of 91 days seen across all 131 historical drawdown events in our database.

The current transition to the yellow zone highlights that the sell-off has extended beyond a typical short-term correction. By crossing the 10% threshold, this pullback joins a specific subset of more prolonged historical declines. We monitor these zone changes because they often signal a shift in market regime or a prolonged period of consolidation.

Valuation Versus Its Own Record

To understand the current -12.6% drawdown, we must look at where the stock's valuation multiples sit within its own historical range. As of the valuation snapshot on 2026-06-18, the price-to-sales (P/S) ratio for Vertex Pharmaceuticals Incorporated (VRTX) is 9.6. This ratio sits in the 22nd percentile of its daily P/S record since June 19, 2006, which is below its own typical historical range. For context, the historical median P/S ratio for the stock over this twenty-year period is 14.7.

Similarly, the enterprise value-to-EBITDA (EV/EBITDA) ratio is 21.2 as of 2026-06-18. This multiple sits in the 33rd percentile of its daily EV/EBITDA record since February 22, 2012. This percentile places the EV/EBITDA multiple within its typical historical range, though it remains below the historical median of 27.7.

These percentiles provide historical context by ranking the current multiples against the stock's own past. A lower percentile indicates that the stock is trading at a multiple lower than it has for the majority of its history. This data is presented strictly as historical context and does not constitute a recommendation or a sign of an undervalued asset.

Analyzing these multiples since their respective inception dates of 2006-06-19 and 2012-02-22 provides a deep historical baseline. The P/S percentile of 22% indicates that the stock has traded at a higher P/S ratio for 78% of the days over the last two decades. The EV/EBITDA percentile of 33% similarly shows that the stock has carried a higher cash-flow multiple for 67% of the days since 2012.

Historical Comparison: How Past 10% Pullbacks Played Out

Our database has tracked 131 total drawdown events for Vertex Pharmaceuticals Incorporated (VRTX). Across all of these events, the average maximum drawdown was -9.6%, with an average duration of 91 days. The current drawdown of -12.6% has already surpassed both of these historical averages.

To put the current 516-day decline into perspective, we must isolate the times the stock dropped 10% or more from its peak. Our data shows this has occurred 39 times in the stock's history. The average duration of these comparable drops is 283 days, meaning the current 516-day drawdown is nearly double the historical average duration for a double-digit decline.

When a stock exceeds both its average drawdown depth and its average duration, it indicates a structural shift in investor behavior. In the past, pullbacks of this magnitude were resolved much faster, allowing the stock to reclaim its prior highs within three quarters on average. The current 516-day period of underperformance suggests that the market is taking longer to digest the company's current growth profile.

The fact that the current drawdown has lasted 516 days suggests a slower, more grinding correction than the average historical 10% drop. While the depth of -12.6% is moderately elevated, the time spent below the peak is the primary factor driving the Drawdown Severity Score™ to 2.0.

What Is Driving the Market Sentiment Around Vertex?

Recent market news highlights the mixed sentiment surrounding the stock during this drawdown period. According to Yahoo Finance, Vertex has experienced days where the broader market gained while its stock declined, drawing attention to its relative underperformance during certain trading sessions. This disconnect has led some investors to ask whether the stock is a stable holding at current levels.

At the same time, institutional activity has shown shifting patterns. According to GuruFocus, the Nia Impact Solutions Fund recently updated its holding history for Vertex Pharmaceuticals Inc, reflecting ongoing adjustments by institutional asset managers. These portfolio reallocations can contribute to the prolonged price consolidation we are observing.

On the pipeline front, market participants are closely watching the company's expansion beyond cystic fibrosis. A report by TradingView questioned whether Vertex's kidney pipeline can power its next growth phase, highlighting both the potential and the execution risks of its developmental drugs. This pipeline uncertainty, combined with broader biotech sector rotations, helps explain why the stock has remained in a drawdown for 516 days.

Additionally, a headline from Yahoo Finance asked whether Vertex is a good stock to buy now, reflecting the intense debate among retail investors regarding the stock's current valuation. While we do not offer investment advice, this discussion underscores the market's focus on identifying potential inflection points during extended drawdowns. The balance between pipeline optimism and short-term performance drag remains a key driver of daily volatility.

Risk Thresholds and What to Watch Next

As Vertex Pharmaceuticals Incorporated (VRTX) navigates the yellow zone, investors can monitor specific data points to gauge whether the drawdown is stabilizing or deepening. The first key metric is the severity score itself. If the drawdown deepens past -15%, the Drawdown Severity Score™ may rise, signaling a potential shift toward the orange zone.

The second metric to track is the valuation percentile. As of June 18, 2026, the P/S ratio sits in the 22nd percentile, and the EV/EBITDA ratio is in the 33rd percentile. If the stock price continues to slide while earnings and sales remain steady, these percentiles will drift lower. Monitoring whether these multiples find support near their historical minimums or continue to compress will provide critical context.

Finally, the duration of the current drawdown is already at 516 days, which is well above the historical average of 283 days for comparable 10% drops. A break above the previous all-time high of $516.74 is required to officially resolve this drawdown cycle. Until then, the data indicates that Vertex remains in a prolonged, moderately elevated correction phase.